These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1568 related articles for article (PubMed ID: 20926543)
1. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial]. Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383 [TBL] [Abstract][Full Text] [Related]
3. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth. Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450 [TBL] [Abstract][Full Text] [Related]
4. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome. Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645 [TBL] [Abstract][Full Text] [Related]
5. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age. Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938 [TBL] [Abstract][Full Text] [Related]
7. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age. Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581 [TBL] [Abstract][Full Text] [Related]
8. IGF-1 Levels, Complex Formation, and IGF Bioactivity in Growth Hormone-Treated Children With Prader-Willi Syndrome. Bakker NE; van Doorn J; Renes JS; Donker GH; Hokken-Koelega AC J Clin Endocrinol Metab; 2015 Aug; 100(8):3041-9. PubMed ID: 26050733 [TBL] [Abstract][Full Text] [Related]
9. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy. Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833 [TBL] [Abstract][Full Text] [Related]
10. Growth Hormone Treatment in Children With Prader-Willi Syndrome: Three Years of Longitudinal Data in Prepubertal Children and Adult Height Data From the KIGS Database. Bakker NE; Lindberg A; Heissler J; Wollmann HA; Camacho-Hübner C; Hokken-Koelega AC; J Clin Endocrinol Metab; 2017 May; 102(5):1702-1711. PubMed ID: 28323917 [TBL] [Abstract][Full Text] [Related]
11. IGF-I and IGF-binding protein-3 measurements on filter paper blood spots in children and adolescents on GH treatment: use in monitoring and as markers of growth performance. Das U; Whatmore AJ; Khosravi J; Wales JK; Butler G; Kibirige MS; Diamandi A; Jones J; Patel L; Hall CM; Price DA; Clayton PE Eur J Endocrinol; 2003 Sep; 149(3):179-85. PubMed ID: 12943519 [TBL] [Abstract][Full Text] [Related]
12. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children. Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG; J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand. Wacharasindhu S; Supornsilchai V; Aroonparkmongkol S; Srivuthana S J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422 [TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. Juul A; Kastrup KW; Pedersen SA; Skakkebaek NE J Clin Endocrinol Metab; 1997 Apr; 82(4):1195-201. PubMed ID: 9100596 [TBL] [Abstract][Full Text] [Related]
15. Thyroid hormone levels in children with Prader-Willi syndrome before and during growth hormone treatment. Festen DA; Visser TJ; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC Clin Endocrinol (Oxf); 2007 Sep; 67(3):449-56. PubMed ID: 17716335 [TBL] [Abstract][Full Text] [Related]
16. Effects of growth hormone therapy on cardiac dimensions in children and adolescents with Prader-Willi syndrome. Hauffa BP; Knaup K; Lehmann N; Neudorf U; Nagel B Horm Res Paediatr; 2011; 75(1):56-62. PubMed ID: 20924154 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of diagnostic accuracy of insulin-like growth factor (IGF)-I and IGF-binding protein-3 in growth hormone-deficient children and adults using ROC plot analysis. Boquete HR; Sobrado PG; Fideleff HL; Sequera AM; Giaccio AV; Suárez MG; Ruibal GF; Miras M J Clin Endocrinol Metab; 2003 Oct; 88(10):4702-8. PubMed ID: 14557444 [TBL] [Abstract][Full Text] [Related]
18. Increased IGFBP Proteolysis, IGF-I Bioavailability, and Pappalysin Levels in Children With Prader-Willi Syndrome. Barrios V; Martín-Rivada Á; Martos-Moreno GÁ; Canelles S; Moreno-Macián F; De Mingo-Alemany C; Delvecchio M; Pajno R; Fintini D; Chowen JA; Argente J J Clin Endocrinol Metab; 2024 Aug; 109(9):e1776-e1786. PubMed ID: 38141219 [TBL] [Abstract][Full Text] [Related]
19. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children. Scirè G; Del Bianco C; Spadoni GL; Cianfarani S J Endocrinol Invest; 2008 Feb; 31(2):153-8. PubMed ID: 18362507 [TBL] [Abstract][Full Text] [Related]
20. Effect of severe growth hormone (GH) deficiency due to a mutation in the GH-releasing hormone receptor on insulin-like growth factors (IGFs), IGF-binding proteins, and ternary complex formation throughout life. Aguiar-Oliveira MH; Gill MS; de A Barretto ES; Alcântara MR; Miraki-Moud F; Menezes CA; Souza AH; Martinelli CE; Pereira FA; Salvatori R; Levine MA; Shalet SM; Camacho-Hubner C; Clayton PE J Clin Endocrinol Metab; 1999 Nov; 84(11):4118-26. PubMed ID: 10566659 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]